Early Diagnosis and Prevention of Infections in Cirrhosis

Anand V. Kulkarni; Madhumita Premkumar; Juan P. Arab; Karan Kumar; Mithun Sharma; Nageshwar D. Reddy; Nagaraja R. Padaki; Rajender K. Reddy

doi:10.1055/a-1869-7607

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2022; 42(03): 293-312
DOI: 10.1055/a-1869-7607

Review Article

Early Diagnosis and Prevention of Infections in Cirrhosis

Anand V. Kulkarni

¹Department of Hepatology, Asian Institute of Gastroenterology, Hyderabad, Telangana, India

,

Madhumita Premkumar

²Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

,

Juan P. Arab

³Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile

,

Karan Kumar

⁴Department of Hepatology, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India

,

Mithun Sharma

¹Department of Hepatology, Asian Institute of Gastroenterology, Hyderabad, Telangana, India

,

Nageshwar D. Reddy

¹Department of Hepatology, Asian Institute of Gastroenterology, Hyderabad, Telangana, India

,

Nagaraja R. Padaki

¹Department of Hepatology, Asian Institute of Gastroenterology, Hyderabad, Telangana, India

,

Rajender K. Reddy

⁵Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania

› Institutsangaben

Abstract

Strategies to prevent infection and improve outcomes in patients with cirrhosis. HAV, hepatitis A virus; HBV, hepatitis B virus; COVID-19, novel coronavirus disease 2019; NSBB, nonselective β-blocker; PPI, proton pump inhibitors.

Cirrhosis is a risk factor for infections. Majority of hospital admissions in patients with cirrhosis are due to infections. Sepsis is an immunological response to an infectious process that leads to end-organ dysfunction and death. Preventing infections may avoid the downstream complications, and early diagnosis of infections may improve the outcomes. In this review, we discuss the pathogenesis, diagnosis, and biomarkers of infection; the incremental preventive strategies for infections and sepsi; and the consequent organ failures in cirrhosis. Strategies for primary prevention include reducing gut translocation by selective intestinal decontamination, avoiding unnecessary proton pump inhibitors' use, appropriate use of β-blockers, and vaccinations for viral diseases including novel coronavirus disease 2019. Secondary prevention includes early diagnosis and a timely and judicious use of antibiotics to prevent organ dysfunction. Organ failure support constitutes tertiary intervention in cirrhosis. In conclusion, infections in cirrhosis are potentially preventable with appropriate care strategies to then enable improved outcomes.

Keywords

liver failure - infections - antibiotics - morbidity

Volltext

Referenzen

References
1 Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. Chest 2003; 124 (03) 1016-1020
2 Navasa M, Fernández J, Rodés J. Bacterial infections in liver cirrhosis. Ital J Gastroenterol Hepatol 1999; 31 (07) 616-625
3 Levesque E, Saliba F, Ichaï P, Samuel D. Outcome of patients with cirrhosis requiring mechanical ventilation in ICU. J Hepatol 2014; 60 (03) 570-578
4 Piano S, Singh V, Caraceni P. et al; International Club of Ascites Global Study Group. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology 2019; 156 (05) 1368-1380 .e10
5 Singer M, Deutschman CS, Seymour CW. et al. The third international consensus definitions for sepsis and septic shock (SEPSIS-3). JAMA 2016; 315 (08) 801-810
6 Hensley MK, Deng JC. Acute on chronic liver failure and immune dysfunction: a mimic of sepsis. Semin Respir Crit Care Med 2018; 39 (05) 588-597
7 Arabi YM, Dara SI, Memish Z. et al; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis. Hepatology 2012; 56 (06) 2305-2315
8 Bajaj JS, O'Leary JG, Reddy KR. et al; North American Consortium For The Study Of End-Stage Liver Disease (NACSELD). Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 2014; 60 (01) 250-256
9 Moreau R, Jalan R, Gines P. et al; CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144 (07) 1426-1437 , 1437.e1–1437.e9
10 Arvaniti V, D'Amico G, Fede G. et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139 (04) 1246-1256 , 1256.e1–1256.e5
11 Garcia-Tsao G. Prophylactic antibiotics in cirrhosis: are they promoting or preventing infections?. Clin Liver Dis (Hoboken) 2019; 14 (03) 98-102
12 Bonnel AR, Bunchorntavakul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol 2011; 9 (09) 727-738
13 Borzio M, Salerno F, Piantoni L. et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001; 33 (01) 41-48
14 Fernández J, Prado V, Trebicka J. et al; European Foundation for the Study of Chronic Liver Failure (EF-Clif). Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J Hepatol 2019; 70 (03) 398-411
15 Bajaj JS, O'Leary JG, Reddy KR. et al; NACSELD. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology 2012; 56 (06) 2328-2335
16 Fernández J, Navasa M, Gómez J. et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35 (01) 140-148
17 Bajaj JS, Heuman DM, Hylemon PB. et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60 (05) 940-947
18 Bert F, Panhard X, Johnson J. et al. Genetic background of Escherichia coli isolates from patients with spontaneous bacterial peritonitis: relationship with host factors and prognosis. Clin Microbiol Infect 2008; 14 (11) 1034-1040
19 Terra C, Guevara M, Torre A. et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005; 129 (06) 1944-1953
20 Premkumar M, Devurgowda D, Dudha S. et al. A/H1N1/09 influenza is associated with high mortality in liver cirrhosis. J Clin Exp Hepatol 2019; 9 (02) 162-170
21 Premkumar M, Sarin SK. Current concepts in coagulation profile in cirrhosis and acute-on-chronic liver failure. Clin Liver Dis (Hoboken) 2020; 16 (04) 158-167
22 Kulkarni AV, Kumar P, Sharma M. et al. Pathophysiology and prevention of paracentesis-induced circulatory dysfunction: a concise review. J Clin Transl Hepatol 2020; 8 (01) 42-48
23 Wagener G, Kovalevskaya G, Minhaz M, Mattis F, Emond JC, Landry DW. Vasopressin deficiency and vasodilatory state in end-stage liver disease. J Cardiothorac Vasc Anesth 2011; 25 (04) 665-670
24 Prin M, Bakker J, Wagener G. Hepatosplanchnic circulation in cirrhosis and sepsis. World J Gastroenterol 2015; 21 (09) 2582-2592
25 Kim G, Huh JH, Lee KJ, Kim MY, Shim KY, Baik SK. Relative adrenal insufficiency in patients with cirrhosis: a systematic review and meta-analysis. Dig Dis Sci 2017; 62 (04) 1067-1079
26 Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology 2009; 50 (06) 2022-2033
27 Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol 2015; 62 (02) 437-447
28 Recknagel P, Gonnert FA, Westermann M. et al. Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. PLoS Med 2012; 9 (11) e1001338
29 Yan J, Li S, Li S. The role of the liver in sepsis. Int Rev Immunol 2014; 33 (06) 498-510
30 Tripathi DM, Vilaseca M, Lafoz E. et al. Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension. Gastroenterology 2018; 155 (05) 1564-1577
31 Simonetto DA, Piccolo Serafim L, Gallo de Moraes A, Gajic O, Kamath PS. Management of sepsis in patients with cirrhosis: current evidence and practical approach. Hepatology 2019; 70 (01) 418-428
32 Levy MM, Fink MP, Marshall JC. et al; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003; 31 (04) 1250-1256
33 Thabut D, Massard J, Gangloff A. et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007; 46 (06) 1872-1882
34 Borgonovo A, Baldin C, Maggi DC. et al. Systemic inflammatory response syndrome in patients hospitalized for acute decompensation of cirrhosis. Can J Gastroenterol Hepatol 2021; 2021: 5581587
35 Piano S, Bartoletti M, Tonon M. et al. Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections. Gut 2018; 67 (10) 1892-1899
36 Augustinho FC, Zocche TL, Borgonovo A. et al. Applicability of Sepsis-3 criteria and quick Sequential Organ Failure Assessment in patients with cirrhosis hospitalised for bacterial infections. Liver Int 2019; 39 (02) 307-315
37 Lan P, Wang SJ, Shi QC. et al. Comparison of the predictive value of scoring systems on the prognosis of cirrhotic patients with suspected infection. Medicine (Baltimore) 2018; 97 (28) e11421
38 Kulkarni AV, Tirumalle S, Premkumar M. et al. Primary norfloxacin prophylaxis for APASL-defined acute-on-chronic liver failure: a placebo-controlled double-blind randomized trial. Am J Gastroenterol 2022; 117 (04) 607-616
39 Philips CA, Ahamed R, Rajesh S, George T, Mohanan M, Augustine P. Update on diagnosis and management of sepsis in cirrhosis: current advances. World J Hepatol 2020; 12 (08) 451-474
40 Lin S, Huang Z, Wang M. et al. Interleukin-6 as an early diagnostic marker for bacterial sepsis in patients with liver cirrhosis. J Crit Care 2015; 30 (04) 732-738
41 Bernsmeier C, Cavazza A, Fatourou EM. et al. Leucocyte ratios are biomarkers of mortality in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. Aliment Pharmacol Ther 2020; 52 (05) 855-865
42 Kwon JH, Jang JW, Kim YW. et al. The usefulness of C-reactive protein and neutrophil-to-lymphocyte ratio for predicting the outcome in hospitalized patients with liver cirrhosis. BMC Gastroenterol 2015; 15: 146
43 Jalan R, Fernandez J, Wiest R. et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014; 60 (06) 1310-1324
44 Trieb M, Rainer F, Stadlbauer V. et al. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. J Hepatol 2020; 73 (01) 113-120
45 Kulkarni AV, Anand L, Vyas AK. et al. Omega-3 fatty acid lipid emulsions are safe and effective in reducing endotoxemia and sepsis in acute-on-chronic liver failure: An open-label randomized controlled trial. J Gastroenterol Hepatol 2021; 36 (07) 1953-1961
46 Wen X, Tong J, Yao M, Hu J, Lu F. Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF. J Hepatol 2021; 75 (01) 243-245
47 Stauber RE, Scharnagl H, Marsche G. Reply to: “Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF”. J Hepatol 2021; 75 (01) 245-246
48 Morin EE, Guo L, Schwendeman A, Li XA. HDL in sepsis - risk factor and therapeutic approach. Front Pharmacol 2015; 6: 244
49 Fischer P, Grigoras C, Bugariu A. et al. Are presepsin and resistin better markers for bacterial infection in patients with decompensated liver cirrhosis?. Dig Liver Dis 2019; 51 (12) 1685-1691
50 Yagmur E, Trautwein C, Gressner AM, Tacke F. Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol 2006; 101 (06) 1244-1252
51 Tornai D, Vitalis Z, Jonas A. et al. Increased sTREM-1 levels identify cirrhotic patients with bacterial infection and predict their 90-day mortality. Clin Res Hepatol Gastroenterol 2021; 45 (05) 101579
52 Tornai T, Vitalis Z, Sipeki N. et al. Macrophage activation marker, soluble CD163, is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection. Liver Int 2016; 36 (11) 1628-1638
53 Reuken PA, Kiehntopf M, Stallmach A, Bruns T. Mid-regional pro-adrenomedullin (MR-proADM): an even better prognostic biomarker than C-reactive protein to predict short-term survival in patients with decompensated cirrhosis at risk of infection?. J Hepatol 2012; 57 (05) 1156-1158 , author reply 1158–1159
54 Kaur S, Hussain S, Kolhe K. et al. Elevated plasma ICAM1 levels predict 28-day mortality in cirrhotic patients with COVID-19 or bacterial sepsis. JHEP Rep 2021; 3 (04) 100303
55 Tsiakalos A, Karatzaferis A, Ziakas P, Hatzis G. Acute-phase proteins as indicators of bacterial infection in patients with cirrhosis. Liver Int 2009; 29 (10) 1538-1542
56 Lazzarotto C, Ronsoni MF, Fayad L. et al. Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis. Ann Hepatol 2013; 12 (04) 599-607
57 Yuan LY, Ke ZQ, Wang M, Li Y. Procalcitonin and C-reactive protein in the diagnosis and prediction of spontaneous bacterial peritonitis associated with chronic severe hepatitis B. Ann Lab Med 2013; 33 (06) 449-454
58 Lin KH, Wang FL, Wu MS. et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: a systematic review and meta-analysis. Diagn Microbiol Infect Dis 2014; 80 (01) 72-78
59 Denning NL, Aziz M, Gurien SD, Wang P. DAMPs and NETs in Sepsis. Front Immunol 2019; 10: 2536
60 Yoo H, Im Y, Ko RE, Lee JY, Park J, Jeon K. Association of plasma level of high-mobility group box-1 with necroptosis and sepsis outcomes. Sci Rep 2021; 11 (01) 9512
61 Pregernig A, Müller M, Held U, Beck-Schimmer B. Prediction of mortality in adult patients with sepsis using six biomarkers: a systematic review and meta-analysis. Ann Intensive Care 2019; 9 (01) 125
62 Nikkari S, McLaughlin IJ, Bi W, Dodge DE, Relman DA. Does blood of healthy subjects contain bacterial ribosomal DNA?. J Clin Microbiol 2001; 39 (05) 1956-1959
63 Bajpai V, Gupta E, Mitra LG. et al. Spectrum of respiratory viral infections in liver disease patients with cirrhosis admitted in critical care unit. J Lab Physicians 2019; 11 (04) 356-360
64 Schütte A, Ciesek S, Wedemeyer H, Lange CM. Influenza virus infection as precipitating event of acute-on-chronic liver failure. J Hepatol 2019; 70 (04) 797-799
65 Pati GK, Singh A, Misra B. et al. Acute-on-chronic liver failure (ACLF) in Coastal Eastern India: “a single-center experience”. J Clin Exp Hepatol 2016; 6 (01) 26-32
66 Ekpanyapong S, Reddy KR. Infections in cirrhosis. Curr Treat Options Gastroenterol 2019; 17 (02) 254-270
67 Kumar P, Sharma M, Sulthana SF, Kulkarni A, Rao PN, Reddy DN. Severe acute respiratory syndrome coronavirus 2-related acute-on-chronic liver failure. J Clin Exp Hepatol 2021; 11 (03) 404-406
68 Kulkarni AV, Parthasarathy K, Kumar P. et al. Early liver transplantation after COVID-19 infection: The first report. Am J Transplant 2021; 21 (06) 2279-2284
69 Fix OK, Blumberg EA, Chang KM. et al; AASLD COVID-19 Vaccine Working Group. American association for the study of liver diseases expert panel consensus statement: vaccines to prevent coronavirus disease 2019 infection in patients with liver disease. Hepatology 2021; 74 (02) 1049-1064
70 Bajaj JS, Kamath PS, Reddy KR. The evolving challenge of infections in cirrhosis. N Engl J Med 2021; 384 (24) 2317-2330
71 Leise MD, Talwalkar JA. Immunizations in chronic liver disease: what should be done and what is the evidence. Curr Gastroenterol Rep 2013; 15 (01) 300
72 Caraceni P, Riggio O, Angeli P. et al; ANSWER Study Investigators. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet 2018; 391 (10138): 2417-2429
73 Mücke MM, Mücke VT, Graf C. et al. Efficacy of norfloxacin prophylaxis to prevent spontaneous bacterial peritonitis: a systematic review and meta-analysis. Clin Transl Gastroenterol 2020; 11 (08) e00223
74 Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. Gut 2020; 69 (05) 953-962
75 Tandon P, Ismond KP, Riess K. et al. Exercise in cirrhosis: translating evidence and experience to practice. J Hepatol 2018; 69 (05) 1164-1177
76 Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodés J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37 (04) 902-908
77 Severi C, Tattoli I, Romano G, Corleto VD, Delle Fave G. Beta3-adrenoceptors: relaxant function and mRNA detection in smooth muscle cells isolated from the human colon. Can J Physiol Pharmacol 2004; 82 (07) 515-522
78 Reiberger T, Ferlitsch A, Payer BA. et al; Vienna Hepatic Hemodynamic Lab. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 2013; 58 (05) 911-921
79 Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Rep 2019; 2 (01) 100063
80 Senzolo M, Cholongitas E, Burra P. et al. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009; 29 (08) 1189-1193
81 Kulkarni AV, Rabiee A, Mohanty A. Management of portal hypertension. J Clin Exp Hepatol 2022; (e-pub ahead of print)
82 Villanueva C, Albillos A, Genescà J. et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019; 393 (10181): 1597-1608
83 Li DK, Chung RT. Use of proton pump inhibitors in chronic liver diseases. Clin Liver Dis (Hoboken) 2018; 10 (06) 148-151
84 De Roza MA, Kai L, Kam JW. et al. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25 (33) 4933-4944
85 Janka T, Tornai T, Borbély B. et al. Deleterious effect of proton pump inhibitors on the disease course of cirrhosis. Eur J Gastroenterol Hepatol 2020; 32 (02) 257-264
86 Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther 2012; 36 (09) 866-874
87 China L, Maini A, Skene SS. et al. Albumin counteracts immune-suppressive effects of lipid mediators in patients with advanced liver disease. Clin Gastroenterol Hepatol 2018; 16 (05) 738-747 .e7
88 Gioannini TL, Zhang D, Teghanemt A, Weiss JP. An essential role for albumin in the interaction of endotoxin with lipopolysaccharide-binding protein and sCD14 and resultant cell activation. J Biol Chem 2002; 277 (49) 47818-47825
89 Carvalho JR, Verdelho Machado M. New insights about albumin and liver disease. Ann Hepatol 2018; 17 (04) 547-560
90 Oettl K, Birner-Gruenberger R, Spindelboeck W. et al. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J Hepatol 2013; 59 (05) 978-983
91 Gentilini P, Casini-Raggi V, Di Fiore G. et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999; 30 (04) 639-645
92 Romanelli RG, La Villa G, Barletta G. et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 2006; 12 (09) 1403-1407
93 Solà E, Solé C, Simón-Talero M. et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol 2018; 69 (06) 1250-1259
94 Di Pascoli M, Fasolato S, Piano S, Bolognesi M, Angeli P. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver Int 2019; 39 (01) 98-105
95 Sharma P, Puri P, Bansal N. et al. Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites. Eur J Gastroenterol Hepatol 2021; 33 (1S, suppl 1): e499-e504
96 Fernández J, Clària J, Amorós A. et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology 2019; 157 (01) 149-162
97 Giannelli V, Di Gregorio V, Iebba V. et al. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol 2014; 20 (45) 16795-16810
98 Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104 (09) 1223-1233
99 Ginés P, Rimola A, Planas R. et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12 (4, pt. 1): 716-724
100 Rimola A, García-Tsao G, Navasa M. et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000; 32 (01) 142-153
101 Grangé JD, Roulot D, Pelletier G. et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol 1998; 29 (03) 430-436
102 Moreau R, Elkrief L, Bureau C. et al; NORFLOCIR Trial Investigators. Effects of long-term norfloxacin therapy in patients with advanced cirrhosis. Gastroenterology 2018; 155 (06) 1816-1827 .e9
103 Caraceni P, Abraldes JG, Ginès P, Newsome PN, Sarin SK. The search for disease-modifying agents in decompensated cirrhosis: from drug repurposing to drug discovery. J Hepatol 2021; 75 (Suppl. 01) S118-S134
104 Tazi KA, Moreau R, Hervé P. et al. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. Gastroenterology 2005; 129 (01) 303-314
105 Girleanu I, Trifan A, Huiban L. et al. The risk of Clostridioides difficile infection in cirrhotic patients receiving norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis-a real life cohort. Medicina (Kaunas) 2021; 57 (09) 57
106 Fernández J, Acevedo J, Castro M. et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55 (05) 1551-1561
107 Salerno F, Borzio M, Pedicino C. et al; AISF Investigators. The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. Liver Int 2017; 37 (01) 71-79
108 Lontos S, Shelton E, Angus PW. et al. A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients. J Dig Dis 2014; 15 (05) 260-267
109 Terg R, Fassio E, Guevara M. et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol 2008; 48 (05) 774-779
110 Yim HJ, Suh SJ, Jung YK. et al. Daily norfloxacin vs. weekly ciprofloxacin to prevent spontaneous bacterial peritonitis: a randomized controlled trial. Am J Gastroenterol 2018; 113 (08) 1167-1176
111 Montagnese S, Russo FP, Amodio P. et al. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis 2019; 51 (02) 190-205
112 Hanouneh MA, Hanouneh IA, Hashash JG. et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol 2012; 46 (08) 709-715
113 Elfert A, Abo Ali L, Soliman S, Ibrahim S, Abd-Elsalam S. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 2016; 28 (12) 1450-1454
114 Kamal F, Khan MA, Khan Z. et al. Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2017; 29 (10) 1109-1117
115 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69 (02) 406-460
116 Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292 (5519): 1160-1164
117 Lee TS, Chang CC, Zhu Y, Shyy JY. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 2004; 110 (10) 1296-1302
118 Pleiner J, Schaller G, Mittermayer F. et al. Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 2004; 110 (21) 3349-3354
119 La Mura V, Pasarín M, Meireles CZ. et al. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology 2013; 57 (03) 1172-1181
120 Novack V, Terblanche M, Almog Y. Do statins have a role in preventing or treating sepsis?. Crit Care 2006; 10 (01) 113
121 Stolf AM, Lívero FdosR, Dreifuss AA. et al. Effects of statins on liver cell function and inflammation in septic rats. J Surg Res 2012; 178 (02) 888-897
122 Tleyjeh IM, Kashour T, Hakim FA. et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009; 169 (18) 1658-1667
123 Parihar SP, Guler R, Brombacher F. Statins: a viable candidate for host-directed therapy against infectious diseases. Nat Rev Immunol 2019; 19 (02) 104-117
124 Motzkus-Feagans C, Pakyz AL, Ratliff SM, Bajaj JS, Lapane KL. Statin use and infections in Veterans with cirrhosis. Aliment Pharmacol Ther 2013; 38 (06) 611-618
125 Abraldes JG, Villanueva C, Aracil C. et al; BLEPS Study Group. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 2016; 150 (05) 1160-1170 .e3
126 Mohanty A, Tate JP, Garcia-Tsao G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis. Gastroenterology 2016; 150 (02) 430-40 .e1
127 Bishnu S, Ahammed SM, Sarkar A. et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. Eur J Gastroenterol Hepatol 2018; 30 (01) 54-59
128 Wong JC, Chan HL, Tse YK, Yip TC, Wong VW, Wong GL. Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. Aliment Pharmacol Ther 2017; 46 (10) 1001-1010
129 Gaia S, Olivero A, Smedile A. et al. Multiple courses of G-CSF in patients with decompensated cirrhosis: consistent mobilization of immature cells expressing hepatocyte markers and exploratory clinical evaluation. Hepatol Int 2013; 7 (04) 1075-1083
130 Garg V, Garg H, Khan A. et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology 2012; 142 (03) 505-512 .e1
131 Khanam A, Trehanpati N, Garg V. et al. Altered frequencies of dendritic cells and IFN-gamma-secreting T cells with granulocyte colony-stimulating factor (G-CSF) therapy in acute-on- chronic liver failure. Liver Int 2014; 34 (04) 505-513
132 Kedarisetty CK, Anand L, Bhardwaj A. et al. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis. Gastroenterology 2015; 148 (07) 1362-70 .e7
133 Anand L, Bihari C, Kedarisetty CK. et al. Early cirrhosis and a preserved bone marrow niche favour regenerative response to growth factors in decompensated cirrhosis. Liver Int 2019; 39 (01) 115-126
134 Verma N, Kaur A, Sharma R. et al. Outcomes after multiple courses of granulocyte colony-stimulating factor and growth hormone in decompensated cirrhosis: A randomized trial. Hepatology 2018; 68 (04) 1559-1573
135 Prajapati R, Arora A, Sharma P, Bansal N, Singla V, Kumar A. Granulocyte colony-stimulating factor improves survival of patients with decompensated cirrhosis: a randomized-controlled trial. Eur J Gastroenterol Hepatol 2017; 29 (04) 448-455
136 Philips CA, Augustine P, Rajesh S. et al. Granulocyte colony-stimulating factor use in decompensated cirrhosis: lack of survival benefit. J Clin Exp Hepatol 2020; 10 (02) 124-134
137 Newsome PN, Fox R, King AL. et al. Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. Lancet Gastroenterol Hepatol 2018; 3 (01) 25-36
138 Sharma M, Kulkarni A, Sasikala M. et al. Long-term outcome of autologous hematopoietic stem cell infusion in cirrhosis: waning effect over time. J Clin Transl Hepatol 2020; 8 (04) 385-390
139 Ferrer R, Martin-Loeches I, Phillips G. et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014; 42 (08) 1749-1755
140 Merli M, Lucidi C, Di Gregorio V. et al. An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: a randomized trial. Hepatology 2016; 63 (05) 1632-1639
141 Wong F, Piano S, Singh V. et al; International Club of Ascites Global Study Group. Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. J Hepatol 2021; 74 (02) 330-339
142 Fernández J, Acevedo J, Wiest R. et al; European Foundation for the Study of Chronic Liver Failure. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut 2018; 67 (10) 1870-1880
143 Mücke MM, Rumyantseva T, Mücke VT. et al. Bacterial infection-triggered acute-on-chronic liver failure is associated with increased mortality. Liver Int 2018; 38 (04) 645-653
144 Fernández J, Tandon P, Mensa J, Garcia-Tsao G. Antibiotic prophylaxis in cirrhosis: good and bad. Hepatology 2016; 63 (06) 2019-2031
145 China L, Freemantle N, Forrest E. et al; ATTIRE Trial Investigators. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med 2021; 384 (09) 808-817
146 Fernández J, Angeli P, Trebicka J. et al. Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 2020; 18 (04) 963-973 .e14
147 Mahmud N, Chapin S, Goldberg DS, Reddy KR, Taddei TH, Kaplan DE. Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. J Hepatol 2022; 76 (05) 1100-1108
148 Plauth M, Bernal W, Dasarathy S. et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr 2019; 38 (02) 485-521
149 Schaible UE, Kaufmann SH. Malnutrition and infection: complex mechanisms and global impacts. PLoS Med 2007; 4 (05) e115
150 Lucidi C, Lattanzi B, Di Gregorio V. et al. A low muscle mass increases mortality in compensated cirrhotic patients with sepsis. Liver Int 2018; 38 (05) 851-857
151 Ebadi M, Montano-Loza AJ. Insights on clinical relevance of sarcopenia in patients with cirrhosis and sepsis. Liver Int 2018; 38 (05) 786-788
152 Kim HY, Jang JW. Sarcopenia in the prognosis of cirrhosis: going beyond the MELD score. World J Gastroenterol 2015; 21 (25) 7637-7647
153 Bischoff SC, Bernal W, Dasarathy S. et al. ESPEN practical guideline: clinical nutrition in liver disease. Clin Nutr 2020; 39 (12) 3533-3562
154 Fernández J, Piano S, Bartoletti M, Wey EQ. Management of bacterial and fungal infections in cirrhosis: The MDRO challenge. J Hepatol 2021; 75 (Suppl. 01) S101-S117
155 Piano S, Tonon M, Angeli P. Changes in the epidemiology and management of bacterial infections in cirrhosis. Clin Mol Hepatol 2021; 27 (03) 437-445
156 van Schaik W. The human gut resistome. Philos Trans R Soc Lond B Biol Sci 2015; 370 (1670): 20140087
157 Werner G, Coque TM, Franz CM. et al. Antibiotic resistant enterococci-tales of a drug resistance gene trafficker. Int J Med Microbiol 2013; 303 (6-7): 360-379
158 Patel VC, Williams R. Antimicrobial resistance in chronic liver disease. Hepatol Int 2020; 14 (01) 24-34
159 Alcock BP, Raphenya AR, Lau TTY. et al. CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. Nucleic Acids Res 2020; 48 (D1): D517-D525
160 van Duin D, Paterson DL. Multidrug-resistant bacteria in the community: trends and lessons learned. Infect Dis Clin North Am 2016; 30 (02) 377-390
161 Powell EE, Skoien R, Rahman T. et al. Increasing hospitalization rates for cirrhosis: overrepresentation of disadvantaged Australians. EClinicalMedicine 2019; 11: 44-53
162 Calder PC. Immunonutrition. BMJ 2003; 327 (7407): 117-118
163 Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002; 21 (06) 495-505
164 Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?. Br J Clin Pharmacol 2013; 75 (03) 645-662
165 Kang JX, Weylandt KH. Modulation of inflammatory cytokines by omega-3 fatty acids. Subcell Biochem 2008; 49: 133-143
166 Shamsaddini A, Gillevet PM, Acharya C. et al. Impact of antibiotic resistance genes in gut microbiome of patients with cirrhosis. Gastroenterology 2021; 161 (02) 508-521 .e7
167 Bajaj JS, Shamsaddini A, Fagan A. et al. Fecal microbiota transplant in cirrhosis reduces gut microbial antibiotic resistance genes: analysis of two trials. Hepatol Commun 2020; 5 (02) 258-271
168 Duan Y, Llorente C, Lang S. et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 2019; 575 (7783): 505-511
169 Bakhshinejad B, Sadeghizadeh M. Bacteriophages and their applications in the diagnosis and treatment of hepatitis B virus infection. World J Gastroenterol 2014; 20 (33) 11671-11683
170 Górski A, Jończyk-Matysiak E, Łusiak-Szelachowska M, Międzybrodzki R, Weber-Dąbrowska B, Borysowski J. The potential of phage therapy in sepsis. Front Immunol 2017; 8: 1783
171 Engelmann C, Adebayo D, Oria M. et al. Recombinant alkaline phosphatase prevents acute on chronic liver failure. Sci Rep 2020; 10 (01) 389
172 Kiffer-Moreira T, Sheen CR, Gasque KC. et al. Catalytic signature of a heat-stable, chimeric human alkaline phosphatase with therapeutic potential. PLoS One 2014; 9 (02) e89374
173 Matsunaga N, Tsuchimori N, Matsumoto T, Ii M. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol 2011; 79 (01) 34-41
174 Macnaughtan J, Albillos A, Kerbert A. et al. A double blind, randomised, placebo-controlled study to assess safety and tolerability of oral enterosorbent yaq-001 in cirrhotic patients. Gut 2021; 70 (Suppl. 03) A5-A6
175 Úbeda M, Lario M, Muñoz L. et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J Hepatol 2016; 64 (05) 1049-1057
176 O'Brien AJ, Fullerton JN, Massey KA. et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat Med 2014; 20 (05) 518-523
177 Agarwal B, Saliba F, Tomescu DR. et al. P076 A multi-centre, randomized controlled study, to evaluate the safety and performance of the DIALIVE liver dialysis device in patients with acute on chronic liver failure (ACLF) versus standard of care (SOC)(ALIVER Consortium). Gut 2021; 70 (Suppl. 03) A54
178 Cañizares RB, Saliba F, Tomescu D. et al. P077 Pathophysiological basis of resolution of acute-on-chronic liver failure (ACLF) induced by the novel liver dialysis device, DIALIVE (ALIVER consortium). Gut 2021; 70 (Suppl. 03) A55

Zusatzmaterial

Supplementary Material